Navigation Links
URAC Announces Accreditation Standards for Comprehensive Wellness Programs
Date:11/19/2008

s are seeking ways to measure the effectiveness of wellness programs. Accreditation is a critical tool employers and purchasers can use to evaluate vendors on a level playing field."

The new Comprehensive Wellness standards and measures were developed by an expert advisory group of employers, health plans, consumer representatives, public benefits organizations, health care professional associations, providers and wellness companies. The program-specific standards fall into five broad categories, creating an evaluation framework for wellness programs that focuses on individual health improvement and risk reduction:

  • Assessment: Includes risk identification and risk awareness program components, such as the use of Health Risk Assessments;
  • Interventions: Addresses overall program design, health coaching, and use of consumer participation incentives, education and communications aspects of wellness programs;
  • Evaluation: Focuses on how the wellness organization calculates, measures, and reports participant progress and overall clinical and financial program success to the client;
  • Integration: Focuses on an organization's ability and willingness to coordinate with other organizations, operations, and programs already in place; and
  • Measurement: Focuses on producing and reporting to purchasers and the public on a specified set of performance measures.

"The Comprehensive Wellness program was developed as part of URAC's commitment to consumer empowerment and protection," said Alan P. Spielman, URAC's president and CEO. "Wellness organizations and employers have recognized the need to support individuals in the improvement and maintenance of their health, and URAC's standards and measures provide a meaningful and actionable framework for wellness program evaluat
'/>"/>

SOURCE URAC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. MDS Inc. Announces Appointment of James S.A. MacDonald as Chairman of Board of Directors
2. USA-ONE Interactive Announces Document Management Solutions That Meet the Needs of Individual Industries
3. Barr Announces Agreements on Nasacort(R) AQ, Allegra(R) D-12 and Allegra(R) Patent Challenges
4. Acumen Fund Announces New Investments In Pakistan To Build Scalable Business That Serve The Poor
5. QC Sciences™ Announces Innovative Solution to Reduce Laboratory Costs : The NuView System™ For Non-Gynecologic Cytology Affords Substantial Savings
6. Capella University Announces $50,000 in Scholarships to Graduate Students in Mental Health Services : Ten students are awarded scholarships at online university
7. Message Archiving Leader Privacy Networks Announces Free Anti-Spam Software to Businesses and Organizations
8. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
9. Pregis Announces Third Quarter 2008 Financial Results
10. eDiets.com(R) Announces Q3 2008 Results
11. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Catholics for Choice Statement on Healthcare Reform Bill 60931 1Catholics for Choice Statement on Healthcare Reform Bill 60931 2Findings show nanomedicine promising for treating spinal cord injuries 10653 1Findings show nanomedicine promising for treating spinal cord injuries 10653 2Findings show nanomedicine promising for treating spinal cord injuries 10653 3APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 60929 1APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 60929 2